Merck and Moderna Announce Promising Late-Stage Trial Results for Personalized Melanoma Vaccine
In a significant development for cancer treatment, Merck and Moderna have reported positive results from a late-stage clinical trial for a personalized mRNA cancer vaccine. The vaccine demonstrated promise in extending the lifespan of patients with melanoma, particularly those at…
San Francisco Oakland San Jose, CA, August 19, 2026 —
Merck and Moderna have announced encouraging outcomes from a late-stage clinical trial involving a personalized mRNA cancer vaccine. The investigational treatment, developed for melanoma patients, has shown potential in extending survival for individuals at high risk of recurrence.
The collaboration between Merck and Moderna focused on a vaccine tailored to individual tumors, aiming to stimulate the immune system to target and eliminate cancer cells. The trial results indicate that the personalized vaccine, when used in conjunction with Merck’s existing immunotherapy drug, Keytruda (pembrolizumab), demonstrated a positive impact on patient outcomes.
Specifically, the vaccine showed promise in reducing the risk of cancer recurrence or death in patients with stage III/IV melanoma who had undergone complete surgical resection. Melanoma is a form of skin cancer that can be aggressive, and identifying effective treatments for high-risk patients is a critical area of cancer research.
Further details regarding the specific metrics of survival benefit and the exact percentage reduction in risk were not immediately available. The companies have indicated that they plan to present detailed data from the trial at an upcoming medical conference and will engage with regulatory authorities to discuss the findings.
The development marks a significant step forward for personalized cancer therapies, leveraging mRNA technology, which has gained prominence in recent years. This approach represents a shift towards treatments that are customized to the unique genetic makeup of a patient’s cancer.
The trial’s success, if further validated, could pave the way for a new class of cancer treatments that harness the body’s own immune system in a highly targeted manner. The continued investigation and potential approval of such personalized vaccines could significantly alter the treatment landscape for melanoma and potentially other types of cancer in the future.
Story summarized from the original created by ABCNews on abc7.com, see more information here.
